Member Info for Blessed22

RSI is 62 getting positive in the last two trading sessions.
Stochastic is 46

Far from being overbought.

The stock was almost near to be oversold last week!

That's what i clearly see

Couldn't resist a 2.5k top up at 180

Gap has been closed one way or another, the volume is low and lower 180s retested as expected.

I won't be surprised to see a decent price action north from now until close of play.

Wanted to trade but better stay put.
Remember that the majority of share are in II hands and imo we ll soon be back above 200.

If it stays like this one can only add a few more.

I think SnG mcap is extremely undervalued at the moment.
After all the milestones achieved, an international phase3 near completion, support from NIH in the US and all the previous data the SP is not yet reflecting this.

However, is worth to note that there's is still a seller and after the last months the majority of shares are in II hands compared to last yeat when PI counted for around 60%.
This would make you think that any positive catalyst will gradually move the SP higher.

One could be some support from Barda imo.
In the next rns regarding A2 P3 we shall know more.

I would think that for a biotech company at this stage the mcap should be at least 2/300m more than what is today.

I ll go for 3£+/- end of month beginning of December.

We shall see but I am expecting a rerate in anticipation of a successful outcome.

All the very best

https://www.bmj.com/content/375/bmj.n2635

"for researchers who were testing Pfizer’s vaccine at several sites in Texas during that autumn, speed may have come at the cost of data integrity and patient safety. A regional director who was employed at the research organisation Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding".

In November last year we had two webinar one on the 18th one the 30th if I remember right and both RM and T. Wilkinson did say results in a cpls of weeks.

I remember very well.
And I remember very well what the results were.
Given the similarity of the Active-2 trial being at home I wouldn't gamble on these results this time.

Sprinter is another story but all in all it may take another year.

As per my previous post 132 has been it while I write.

Early 2002 could mean March/April in RM vocabulary.

Like when on the Nov2020 webinar RM said home trial results in a cpls of weeks and we got them in May of the next year.

And you wonder why people are selling up.

I d rather watch on the side, if the Active-2 prove to be a fiasco people dont want take the risk to lose half of their investment in a day.

Levels are 140 (broken) 132 (to be broken next week) and then 110/120.

Have fun

Everyone is free t to think of charts whatever they want.
The point is that depending on the circumstances they can help you make a more informed decision.

This weekend we had coverage both on papers and from chartists. This should obviously bring more interest no doubt about that.

Regarding the chart we had a long consolidation between 140and160 and we needed a catalyst to move the SP.
Positive news from Polygon brought the SP to another level which is in itself another catalyst.

Bottom line tomorrow will be defenetely interesting to watch even though I am not expecting an RNS.

A positive price action on a Friday often repeats itself on a Monday.

Vox markets

**********

https://www.**********.co.uk/articles/traders-cafe-with-zak-mir-weekend-bulletin-board-heroes-september-11-989d139/

https://www.**********.co.uk/articles/traders-cafe-with-zak-mir-weekend-bulletin-board-heroes-september-11-989d139/

Bullish

https://www.google.com/amp/s/amp.theguardian.com/business/2021/sep/11/a-year-that-changed-the-world-and-medical-companies-fortunes

https://www.google.com/amp/s/amp.theguardian.com/business/2021/sep/11/a-year-that-changed-the-world-and-medical-companies-fortunesSynairgen’s share price has soared by 342% since July 2020 when the University of Southampton spinout made a major breakthrough with a coronavirus treatment. The company has gone from fewer than 20 employees before Covid to about 100, including freelancers. Analysts at Numis are forecasting revenue of up to £582m from the Covid treatment next year.The company’s main drug, developed to treat lung disease COPD, is an inhaled interferon beta that patients self-administer through a hand-held, battery-operated nebuliser. In May, the shares rose again when the company said intermediate trials of the drug, which is delivered directly into patients’ lungs to prevent severe respiratory illness caused by Covid, had shown “potent antiviral activity” against two Covid variants. The tests also demonstrated “broad-spectrum antiviral activity” against other respiratory viruses such as RSV, adenovirus and influenza.Chief executive Richard Marsden says that as the drug “switches on the immune system”, the team is confident it will work against any variant. Assuming clinical trials in 17 countries are successful, Synairgen hopes to file for regulatory approval globally early next year and is scaling up manufacturing.

Given today's volume I wouldn't be surprised to see another tr1 next week from you know who.

Assuming that investors expectations will be met my call for the near future is the SP above 3£ at least.

Who was working the buyer makes me think that is Polygon.

The target is the 160s today.

Polygon was still buying yesterday and imo another US buyer as well given the transactions.
A 250k buy came right at close of day let's see if they carry on buying today.

Considering SNG001 formulation and the method of delivery directly to the lungs I believe that the Phase3 results will be as good as last year.

https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.27072

"Also several evidence supported beneficial effects of IFNs-a/ß on severe MERS-CoV-infected patients19, 20. Different recombinant IFNs (rIFN-a2a, rIFN-a2b, rIFN-ß1a, and rIFN-ß1b) have shown promising effects against MERS-CoV in vitro.21 Regarding similar properties of SARS-CoV-2 with MERS-CoV and SARS-CoV, the abovementioned evidence could be very helpful in selecting promising managements against SARS-CoV-2. Furthermore, SARS-CoV-2 has shown a far greater sensitivity to type I IFNs than SARS-CoV in vitro, which suggests more efficiency in treatment using type I IFNs.

It should be taken into consideration that auto-antibodies (auto-Abs) against type I IFNs have been adverted in some patients. Whereas the severity of COVID-19 was recognized due to neutralizing auto-Abs against type I IFNs among 10% of patients. In such cases, treatment with IFN-? is less effective and it should be redirected to IFN-ß therapy."

https://mobile.twitter.com/NIHDirector/status/1436016691134279685

"Among patients with critical COVID-19, these features include inborn errors of type I interferon (IFN)-mediated immunity (13) as well as the production of autoantibodies against type I IFNs (14, 15). Remarkably, these autoantibodies, which seldom occur in healthy controls and have not been found in asymptomatically infected individuals.

Evidence is emerging that genetic and immunological features that pre-date SARS-CoV-2 infection could play an unexpected pathogenic role in severe disease"

I expect a sudden change of direction this afternoon.
A close near or above 160 to be very optimistic